How does the combination therapy in Japan and Taiwan compare directly with monotherapy?
At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%.[1] ↗
Human Phase III randomized; Japan/Taiwan REDEFINE-5
Specific combinations, formulations, and inclusion criteria; three packaging specifications share literature, not three separate studies.
View the Article Title and Full Citation+
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The Lancet. Diabetes & Endocrinology · Volume and issue year 2026
First published 2026-04-17 · PMID 42009015
DOI 10.1016/S2213-8587(25)00402-4







